ROCÍO
GARCÍA CARBONERO
Profesora asociada de Ciencias de la Salud
Andrés
Cervantes Ruiperez
Publicaciones en las que colabora con Andrés Cervantes Ruiperez (9)
2019
-
Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)
Scientific Reports
-
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
Scientific Reports, Vol. 9, Núm. 1
-
Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer
ESMO Open, Vol. 4, Núm. 4
2017
-
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial
Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 227-235
2015
-
Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer
Cancer Discovery, Vol. 5, Núm. 6, pp. 598-609
2014
-
An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer
Oncologist, Vol. 19, Núm. 4, pp. 350-351
-
Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma
European Journal of Cancer, Vol. 50, Núm. 3, pp. 496-505
2011
-
Treatment recommendations for metastatic colorectal cancer
Clinical and Translational Oncology, Vol. 13, Núm. 3, pp. 162-178
2010
-
SEOM clinical guidelines for the treatment of advanced colorectal cancer
Clinical and Translational Oncology, Vol. 12, Núm. 11, pp. 729-734